Two companies supported by HiTT get outstanding reward.

Two companies supported by HiTT get outstanding reward.

HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.  Qbeast is a ‘Big Data’ analysis platform that allows the indexation and visualization of data in a responsive, clear and intuitive way.   On  February, Barcelona Activa has awarded the Qbeast startup for the best business project with a high technological impact, with an economic contribution of 5.000€, in the framework of the fifth edition of the Preacceleració Program. Qbeast has also obtained an office space in the MediaTIC Incubator. HiTT has pleased worked all along with Qbeast to define its business model and its development path.  Also in February Hospital Vall d’Hebron has published that Hospital Vall d’Hebron has obtained more than € 1M benefit from the licence of a new treatment for a rare disease, representing the highest economic benefit generated by a state research institute by a patent licence. Doctors Ramon Martí (VHIR) and Michio Hirano (Columbia University) discovered the treatment in 2013. Afterwards, they licenced the patent to Modis Therapeutics, an American company, to develop the therapy. HiTT participated in the evidence review to complete the evidence package of the value dossier of the drug.   These two successful stories reinforce the idea of Barcelona as a strong life sciences and health HUB articulated around powerful core formed by public hospitals, pharmaceutical companies and research centres with which HiTT has strong and long-standing relationships.  HiTT is an international market access consultancy with a payer perspective, with offices in Barcelona born in 2013. HiTT focuses its main activity on advising and accompanying institutions, research centres and private companies in the health sector, who wish to develop and implement innovative projects to add value to the health...
Big Data analytical tools project

Big Data analytical tools project

Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures. In order to know which are the needs and the characteristics of the companies that use Big Data analytical tools, HiTT is developing this study through interviews to professionals of different sectors and also, through on-line questionnaires that people that is interested in this topic can answer. We would like to gather as much information as possible to ensure that our analysis reflects the real concerns of the market. HiTT invites the professionals that use big data tools in its analytical procedure, to open this link and answer the questionnaire. Your responses will be kept anonymous. Many thanks in...
Innovative public purchase

Innovative public purchase

During The last two months HiTT has been working in 2 different projects of innovative public purchase, and last week we finally have presented them to the regional health service call. The Innovative public purchase is a tool used by the EU to foster the innovation purchase from the public institutions. It is a contract that public institution offers, to satisfy a present need through an innovative solution. The basis is the purchase through the service demand rather than from the solution supply. Both projects try to redefine the relationship between professionals and patients; the two projects are focused on the information system for the patient profile determination. That is to say, the personalization of the health through the phenotypes analysis and the revealed behaviour, not through the genomic studies. We hope we can continue along these...
Spain’s (and Portugal’s) Market Access – update Oct16

Spain’s (and Portugal’s) Market Access – update Oct16

About 60.000 patients treated from HCV infection. Read more. MOH released data on drug access. 59.000 patients treated this year (52.000 F2-F4). Curation rete is at 97% Targeted patients account for 95.000 patients in Spain. The EU Socialist party presents a proposal on innovation at the EU Parliament, and then presents it to the Spanish parliament, where they get support. Read more. ‘…harmonizing the criteria for pricing and reimbursement to take into account the level of innovation and analysis of economic and social profitability, and establish a European classification of the added value of medicines.’ Spanish AEMPS accepts biosimilar indication extrapolation. Read more. Sol Ruiz, Officer from the AEMPS stated last week after the Spanish Rheumatoid Association meeting that “It is possible to extrapolate indications” and referred to the same arguments used to pass the extrapolation of indications of biosimilars” Portuguese Hospitals to be imposed Biosimilar quotas. Read more. Hospitals Portuguese National Health Service (NHS) will have to reach a minimum quota of 20 percent for biosimilars in 2017, as reported by the National Authority of Medicines and Portuguese Health Products (Infarmed) through a statement . In the policy note issued by the Portuguese news agency, ensure that the objective of this measure is to “increase the savings potential of these drugs, optimizing available resources to facilitate the financing of new innovations.”...
Spain’s Market Access – update Sep16

Spain’s Market Access – update Sep16

POLICY Private health expenditure increases 23%: After cuts in public spending, private expenditure has increased by 23%. Read more. Hospital expenditure is reduced by -3.1% in July. For the 7th month in a row, hospital expenditure is reduced. Read more. …while prescription drug expenditure is further increased by 10%: Interanual drug expenditure has expanded +10% according to data from MoH. Read more.   DRUGS MOH: diagnostic drugs ‘can and should go’ to hospital pharmacy. In a recent meeting at Universidad de Santander (UIMP), an officer from MoH declared that they are hoping to shift diagnostic drugs to hospital pharmacy, as this may induce further savings. Read more. Services in Community pharmacies being expanded. Progressive implementation of remunerated tests in community pharmacies, as part of public health programmes. Services are being paid by public insurers. Read more.   INDUSTRY Farmaindustria presented a programme for professionals and patients to improve adherence. They have been preparing with patients and specialists on solutions to improve patients adherence, a major concern for clinicians and payers. Read more Biosimilars Manufacturers request a comprehensive legislative package. After some years in the market, the Industry is demanding a clear regulation. Read more Andalucia’s tendering attracts 16 manufacturers. After their 9th tender for generic drugs, 16 manufacturers applied for the general tender organised by the Region. Read more Seven businesses closing down per day in the last 4 months. Impressive figures on industrial shutdown in the last months. Read more...